Pfizer Inc
NYSE: PFE
$26.72
Closing Price on November 13, 2024
PFE Articles
Intel, Pfizer, 3M, and Disney launched the DJIA to a solid gain Friday.
Published:
Last Updated:
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
Apple indicated that it will pay $38 billion in repatriation taxes under the new tax law. Apple says that it is already the largest U.S. taxpayer and that a payment of that size likely would be the...
Published:
Last Updated:
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
UnitedHealth, Disney, Pfizer, and General Electric were Monday's laggards among the DJIA stocks.
Published:
Last Updated:
For the Jones Industrial Average to make its 2018 targets, Pfizer and Merck will to have to do their part to help. But they both lagged the markets in 2017.
Published:
Last Updated:
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.
Published:
Last Updated:
Here is a consensus forecast of each of the 30 Dow Jones Industrial stocks, including a forward 12-month consensus analyst price target and an expected 2018 total return on each.
Published:
Last Updated:
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Published:
Last Updated:
One strategy that has been popular each year as investors rebalance and make changes is the so-called Dogs of the Dow.
Published:
Last Updated:
Disney, Pfizer, General Electric, and McDonald's weighed on the DJIA Wednesday.
Published:
Last Updated:
Pfizer has just raised its payout by about 6% and more than doubled what it already had on its buyback plans.
Published:
Last Updated:
Intel, Microsoft, Pfizer, and United Technologies drove the DJIA higher Friday.
Published:
Last Updated:
Shares of Pfizer appeared to be headed for a new high after the company announced that the FDA had approved its treatment for adult patients with active psoriatic arthritis.
Published:
Last Updated:
Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two Phase 1 studies in conjunction with Pfizer.
Published:
Last Updated: